Lyka Labs Share Price
Start SIP in Lyka Labs
Start SIPLyka Labs Performance
Day Range
- Low 143
- High 155
52 Week Range
- Low 98
- High 173
- Open Price155
- Previous Close153
- Volume237820
Lyka Labs Investment Rating
-
Master Rating:
-
Lyka Labs has an operating revenue of Rs. 118.43 Cr. on a trailing 12-month basis. An annual revenue growth of 17% is outstanding, Pre-tax margin of -1% needs improvement, ROE of -3% is poor and needs improvement. The company has a debt to equity of 63%, which is bit higher. The stock from a technical standpoint is comfortably placed above its key moving averages, around 19% and 29% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around 13% from the pivot point (which is extended from the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 49 which is a POOR score indicating inconsistency in earnings, a RS Rating of 67 which is FAIR indicating the recent price performance, Buyer Demand at A which is evident from recent demand for the stock, Group Rank of 63 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment.
EPS Strength
Price Strength
Buyer Demand
Group Rank
| Indicator | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 |
|---|---|---|---|---|---|---|
| Oper Rev Qtr Cr | 30 | 27 | 31 | 27 | 21 | 19 |
| Operating Expenses Qtr Cr | 26 | 25 | 26 | 23 | 19 | 17 |
| Operating Profit Qtr Cr | 4 | 2 | 6 | 4 | 3 | 3 |
| Depreciation Qtr Cr | 2 | 3 | 3 | 3 | 3 | 3 |
| Interest Qtr Cr | 1 | 1 | 1 | 1 | 1 | 3 |
| Tax Qtr Cr | 1 | 0 | 1 | 0 | 0 | 0 |
| Net Profit Qtr Cr | 2 | -2 | 1 | 0 | -2 | -3 |
Lyka Labs Technicals
EMA & SMA
- Bullish Moving Average
- ___
- 8
- Bearish Moving Average
- ___
- 8
- 20 Day
- ₹150.66
- 50 Day
- ₹138.01
- 100 Day
- ₹129.10
- 200 Day
- ₹123.79
- 20 Day
- ₹153.56
- 50 Day
- ₹133.07
- 100 Day
- ₹122.14
- 200 Day
- ₹122.34
Lyka Labs Resistance and Support
| Resistance | |
|---|---|
| First Resistance | 156.92 |
| Second Resistance | 160.94 |
| Third Resistance | 163.40 |
| RSI | 54.99 |
| MFI | 70.99 |
| MACD Single Line | 8.06 |
| MACD | 6.80 |
| Support | |
|---|---|
| First Support | 150.44 |
| Second Support | 147.98 |
| Third Supoort | 143.96 |
Lyka Labs Delivery and Volume
| Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
|---|---|---|---|
| Day | 138,804 | 8,544,774 | 61.56 |
| Week | 297,521 | 13,837,720 | 46.51 |
| 1 Month | 940,814 | 36,870,490 | 39.19 |
| 6 Month | 280,813 | 12,656,256 | 45.07 |
Lyka Labs Result Highlights
Lyka Labs Synopsis
NSE-Medical-Generic Drugs
Lyka Labs is involved in the business activities of Manufacture of medicinal substances used in the manufacture of pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts and esters; glycosides and vegetable alkaloids; chemically pure suger etc.. Company’s Total Operating Revenue is Rs. 80.59 Cr. and Equity Capital is Rs. 30.69 Cr. for the Year ended 31/03/2023. Lyka Labs Ltd. is a Public Limited Listed company incorporated on 29/12/1976 and has its registered office in the State of Gujarat, India. Company’s Corporate Identification Number(CIN) is L24230GJ1976PLC008738 and registration number is 008738.| Market Cap | 506 |
| Sales | 115 |
| Shares in Float | 1.39 |
| No of funds | 14 |
| Yield |
| Book Value | 5.09 |
| U/D Vol ratio | 2.7 |
| LTDebt / Equity | 43 |
| Alpha | 0.04 |
| Beta | 1 |
Lyka Labs Shareholding Pattern
| Owner Name | Jun-24 | Mar-24 | Dec-23 |
|---|---|---|---|
| Promoters | 58.1% | 54.81% | 54.81% |
| Mutual Funds | 0.01% | 0.01% | 0.01% |
| Insurance Companies | 0.37% | 0.4% | 0.4% |
| Foreign Portfolio Investors | 0.15% | 0.17% | 0.17% |
| Financial Institutions/ Banks | |||
| Individual Investors | 31.67% | 33.91% | 34.32% |
| Others | 9.7% | 10.7% | 10.29% |
Lyka Labs Management
| Name | Designation |
|---|---|
| Mr. Babulal Jain | Chairman |
| Mr. Kunal Gandhi | Managing Director & CEO |
| Mr. Yogesh B Shah | Executive Director & CFO |
| Mr. Sandeep P Parikh | Independent Director |
| Mrs. Dhara P Shah | Independent Director |
| Mr. Prashant Godha | Non Executive Director |
| Mr. Shashil Mendosa | Non Executive Director |
Lyka Labs Forecast
Price Estimates
Lyka Labs Corporate Action
| Date | Purpose | Remarks |
|---|---|---|
| 2024-08-09 | Quarterly Results | |
| 2024-05-21 | Audited Results & Others | To consider other business matters |
| 2024-04-16 | Others | inter alia: to allot and issue 26,00,000 Equity Shares upon conversion of 26,00,000 Warrants to Ipca Laboratories Limited, part of a Promoter Group. |
| 2024-02-08 | Quarterly Results | |
| 2023-11-02 | Quarterly Results |
Lyka Labs FAQs
What is Share Price of Lyka Labs ?
Lyka Labs share price is ₹147 As on 19 September, 2024 | 19:11
What is the Market Cap of Lyka Labs ?
The Market Cap of Lyka Labs is ₹487.7 Cr As on 19 September, 2024 | 19:11
What is the P/E ratio of Lyka Labs ?
The P/E ratio of Lyka Labs is 554.2 As on 19 September, 2024 | 19:11
What is the PB ratio of Lyka Labs ?
The PB ratio of Lyka Labs is 7.1 As on 19 September, 2024 | 19:11